 adjuv intravesicular pharmacotherapi superfici bladder cancer bladder cancer carcinoma situ case cancer men year old fifth caus cancer death patient bladder cancer present superfici bladder tumor treatment tumor object diseas prophylaxi tumor recurr deep invas muscl layer bladder transurethr resect primari treatment superfici bladder tumor tumor high recurr rate adjuv intravesicular pharmacotherapi cytotox immunomodulatori drug widespread use past decad clinic investig superfici bladder cancer valuabl inform biolog treatment diseas multivari analys tumor grade stage import prognost variabl avail clinician patient risk muscle-invas metastat bladder cancer studi group low risk tumor recurr invas bladder cancer trial recurr rate adjuv intravesicular pharmacotherapi number drug bacillu calmette-guerin vaccin bcg epodyl mitomycin-c teniposid thiotepa studi adjuv intravesicular pharmacotherapi progress invas bladder cancer high-risk patient superfici bladder cancer addit clinic trial therapi invas metastat bladder cancer disease-fre surviv group addit identif test monoclon antibodi test chromosom analys tumor marker assay high-risk patient therapeut strategi superfici bladder cancer